261 related articles for article (PubMed ID: 25651420)
21. Characteristics of Clinical Studies Used for US Food and Drug Administration Approval of High-Risk Medical Device Supplements.
Zheng SY; Dhruva SS; Redberg RF
JAMA; 2017 Aug; 318(7):619-625. PubMed ID: 28810022
[TBL] [Abstract][Full Text] [Related]
22. Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs.
Puthumana J; Miller JE; Kim J; Ross JS
JAMA Netw Open; 2018 Jun; 1(2):e180283. PubMed ID: 30646072
[TBL] [Abstract][Full Text] [Related]
23. Quantification of US Food and Drug Administration Premarket Approval Statements for High-Risk Medical Devices With Pediatric Age Indications.
Lee SJ; Cho L; Klang E; Wall J; Rensi S; Glicksberg BS
JAMA Netw Open; 2021 Jun; 4(6):e2112562. PubMed ID: 34156454
[TBL] [Abstract][Full Text] [Related]
24. US Food and Drug Administration Approvals of Drugs and Devices Based on Nonrandomized Clinical Trials: A Systematic Review and Meta-analysis.
Razavi M; Glasziou P; Klocksieben FA; Ioannidis JPA; Chalmers I; Djulbegovic B
JAMA Netw Open; 2019 Sep; 2(9):e1911111. PubMed ID: 31509209
[TBL] [Abstract][Full Text] [Related]
25. New orthopedic devices and the FDA.
Sheth U; Nguyen NA; Gaines S; Bhandari M; Mehlman CT; Klein G
J Long Term Eff Med Implants; 2009; 19(3):173-84. PubMed ID: 20939777
[TBL] [Abstract][Full Text] [Related]
26. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
27. Summary of the FDA virtual public workshop on spinal device clinical review held on September 17, 2021.
Devlin VJ; Jean R; Peat CR; Jiang H; Anderson PA; Benson JC; Brodke DS; Golish SR; Kebaish KM; Larson AN; Serhan H
Spine J; 2022 Sep; 22(9):1423-1433. PubMed ID: 35460900
[TBL] [Abstract][Full Text] [Related]
28. Assessing the safety and effectiveness of devices after US Food and Drug Administration approval: FDA-mandated postapproval studies.
Reynolds IS; Rising JP; Coukell AJ; Paulson KH; Redberg RF
JAMA Intern Med; 2014 Nov; 174(11):1773-9. PubMed ID: 25265209
[TBL] [Abstract][Full Text] [Related]
29. An overview of Food and Drug Administration regulation of drugs, biologics, and devices to be used for management of periodontal diseases.
Tylenda CA; Weintraub M
Ann Periodontol; 1997 Mar; 2(1):11-7. PubMed ID: 9151539
[TBL] [Abstract][Full Text] [Related]
30. FDA approval of cardiac implantable electronic devices via original and supplement premarket approval pathways, 1979-2012.
Rome BN; Kramer DB; Kesselheim AS
JAMA; 2014 Jan 22-29; 311(4):385-91. PubMed ID: 24449317
[TBL] [Abstract][Full Text] [Related]
31. The Food and Drug Administration and the regulation of clinical trials for endosseous implants.
Scott PD; Runner S
Ann Periodontol; 1997 Mar; 2(1):284-90. PubMed ID: 9151561
[TBL] [Abstract][Full Text] [Related]
32. The FDA and Ensuring Safety and Effectiveness of Devices, Biologics, and Technology.
Dubin JR; Ibad H; Cil A; Murray M
J Am Acad Orthop Surg; 2022 Jul; 30(14):658-667. PubMed ID: 35797679
[TBL] [Abstract][Full Text] [Related]
33. Medical Device Approvals Through the Premarket Approval Pathway in Obstetrics and Gynecology From 2000 to 2015: Process and Problems.
Walter JR; Hayman E; Tsai S; Ghobadi CW; Xu S
Obstet Gynecol; 2016 Jun; 127(6):1110-1117. PubMed ID: 27159747
[TBL] [Abstract][Full Text] [Related]
34. Pivotal clinical trials of novel ophthalmic drugs and medical devices: retrospective observational study, 2002-2012.
Hwang J; Hwang TJ; Ciolino JB
BMJ Open; 2015 Jun; 5(6):e007987. PubMed ID: 26044760
[TBL] [Abstract][Full Text] [Related]
35. Orbital Implants Receiving Food and Drug Administration Premarket Notification.
Corcoran Ruiz KM; Vaishnav YJ; Desautels J; Schaefer JL; Migliori ME; Yilmaz T
Ophthalmic Plast Reconstr Surg; 2022 Sep-Oct 01; 38(5):503-506. PubMed ID: 35699217
[TBL] [Abstract][Full Text] [Related]
36. Gender bias in studies for Food and Drug Administration premarket approval of cardiovascular devices.
Dhruva SS; Bero LA; Redberg RF
Circ Cardiovasc Qual Outcomes; 2011 Mar; 4(2):165-71. PubMed ID: 21364127
[TBL] [Abstract][Full Text] [Related]
37. The Role of the FDA and Regulatory Approval of New Devices for Diabetes Care.
Jazowski SA; Winn AN
Curr Diab Rep; 2017 Jun; 17(6):40. PubMed ID: 28439847
[TBL] [Abstract][Full Text] [Related]
38. Time to publication of cost-effectiveness analyses for medical devices.
Everhart AO
Am J Manag Care; 2023 May; 29(5):265-268. PubMed ID: 37229785
[TBL] [Abstract][Full Text] [Related]
39. Trials of transvaginal mesh devices for pelvic organ prolapse: a systematic database review of the US FDA approval process.
Heneghan CJ; Goldacre B; Onakpoya I; Aronson JK; Jefferson T; Pluddemann A; Mahtani KR
BMJ Open; 2017 Dec; 7(12):e017125. PubMed ID: 29212782
[TBL] [Abstract][Full Text] [Related]
40. Postmarket Modifications of High-Risk Therapeutic Devices in Otolaryngology Cleared by the US Food and Drug Administration.
Rathi VK; Ross JS; Samuel AM; Mehra S
Otolaryngol Head Neck Surg; 2015 Sep; 153(3):400-8. PubMed ID: 26044785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
